Drug Profile

HSG 4113

Alternative Names: HSG4113

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Glaceum
Class Antihyperglycaemics; Insulin sensitisers; Obesity therapies; Small molecules
Mechanism of Action Insulin receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Obesity

Highest Development Phases

No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

28 Dec 2023 No recent reports of development identified for preclinical development in Obesity in South Korea (PO)
28 Nov 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (PO)
02 Mar 2020 HSG 4113 is available for licensing as of 02 Mar 2020. http://en.glaceum.com/

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com